Psilocybin as a novel treatment for chronic pain.

Autor: Askey T; Department of Pharmacology, School of Pharmacy, University of Reading, Reading, RG6 6UB, UK., Lasrado R; Compass Pathways, London, W1F 0DQ, UK., Maiarú M; Department of Pharmacology, School of Pharmacy, University of Reading, Reading, RG6 6UB, UK., Stephens GJ; Department of Pharmacology, School of Pharmacy, University of Reading, Reading, RG6 6UB, UK.
Jazyk: angličtina
Zdroj: British journal of pharmacology [Br J Pharmacol] 2024 Nov 29. Date of Electronic Publication: 2024 Nov 29.
DOI: 10.1111/bph.17420
Abstrakt: Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti-nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co-morbid with pain. This review primarily explores the utility of preclinical animal models in investigating the potential of psilocybin as an anti-nociceptive agent. Initial studies involving psilocybin in animal models of neuropathic and inflammatory pain are summarised, alongside areas where further research is needed. The potential mechanisms of action, including targeting serotonergic pathways through the activation of 5-HT 2A receptors at both spinal and central levels, as well as neuroplastic actions that improve functional connectivity in brain regions involved in chronic pain, are considered. Current clinical aspects and the translational potential of psilocybin from animal models to chronic pain patients are reviewed. Also discussed is psilocybin's profile as an ideal anti-nociceptive agent, with a wide range of effects against chronic pain and its associated inflammatory or emotional components.
(© 2024 The Author(s). British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)
Databáze: MEDLINE
Externí odkaz: